Evidence map›Paper›PMID 40410300›Full record

ArticleScientific reports2025

Inhibition of Talin2 dedifferentiates myofibroblasts and reverses lung and kidney fibrosis.

Michael J V White, Melis Ozkan, Jorge Emiliano Gomez Medellin, Ani Solanki, Jeffrey A Hubbell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michael J V WhitePritzker School of Molecular Engineering, University of Chicago, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0002-9615-2249
Melis OzkanPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0001-8413-6041
Jorge Emiliano Gomez MedellinPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0003-0963-4678
Ani SolankiAnimal Resources Center, University of Chicago, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0002-7190-7852
Jeffrey A HubbellPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, 60637, USA. j.hubbell@nyu.edu.ORCID http://orcid.org/0000-0003-0276-5456

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrosis is involved in 45% of deaths in the United States, and no treatment exists to reverse progression of the disease. To find novel targets for fibrosis therapeutics, we developed a model for the differentiation of monocytes to myofibroblasts that allowed us to screen for proteins involved in myofibroblast differentiation. Inhibition of a novel protein target generated by our model, talin2, reduces myofibroblast-specific morphology, α-smooth muscle actin content, and collagen I content and lowers the pro-fibrotic secretome of myofibroblasts. We find that knockdown of talin2 de-differentiates myofibroblasts and reverses bleomycin-induced lung fibrosis in mice, and further that Tln2

Indexed as

KidneyKidney DiseasesMyofibroblastsPulmonary FibrosisTalinAnimalsBleomycinCell DifferentiationDisease Models, AnimalFibrosisHumansLungMiceMice, Inbred C57BLMice, KnockoutUreteral ObstructionBleomycinTalin

Identifiers

PMID40410300
PMCPMC12102334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.